MedTrace Logo

Safety of F14 Following Total Knee Replacement

NCT04860635 · Status: SUSPENDED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-11-26

No results posted yet for this study

Summary

Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia

Conditions

  • Analgesia

Interventions

DRUG

F14 (sustained release celecoxib)

Celecoxib in BEPO® drug delivery system

Sponsors & Collaborators

  • Arthritis Innovation Corporation

    lead INDUSTRY

Principal Investigators

  • Jared Foran, MD · Panorama Orthopedics & Spine Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860635 on ClinicalTrials.gov